Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Q1 2023 Earnings Call Transcript
Operator: Good morning. My name is Ryan, and I will be your conference operator today.
Karyopharm Therapeutics Inc. (KPTI)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value (x$1000) | Activity | % Port |
|---|---|---|---|---|---|
| 1. | 65,976,000 | $51,148,346 | 1.68% | ||
| 2. | Avidity Partners Management David Witzke And Michael Gregory | 9,633,911 | $37,475,914 | 1.24% | |
| 3. | Palo Alto Investors William Leland Edwards | 5,675,876 | $22,079,158 | +1% | 1.82% |
| 4. | 25,000,000 | $19,256,425 | 0.37% | ||
| 5. | Rubric Capital Management David Rosen | 4,441,056 | $17,275,708 | -47% | 0.44% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $8.60 | 23,250 | Officer | 131,802 | 2021-05-07 | Filing | |
| $7.82 | 4,000 | Director | 4,000 | 2021-05-06 | Filing | |
| $14.54 | 7,500 | Officer | 7,500 | 2020-08-26 | Filing | |
| $33.00 | 2,000 | Officer | 3,000 | 2015-04-07 | Filing | |
| $29.43 | 1,000 | Officer | 1,000 | 2015-04-06 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $2.24 | 3,536 | Officer, Director | 809,278 | 2023-06-05 | Filing | |
| $2.22 | 631 | Officer | 244,730 | 2023-06-02 | Filing | |
| $3.35 | 3,805 | Officer, Director | 812,814 | 2023-05-04 | Filing | |
| $4.05 | 6,655 | Officer | 158,230 | 2023-04-20 | Filing | |
| $4.03 | 115 | Officer | 164,885 | 2023-04-20 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value (x$1000) | % Port |
|---|---|---|---|---|
| 1. | 10,175,989 | $39,582,783 | 0% | |
| 2. | 9,072,188 | $35,290,810 | 0% | |
| 3. | 7,503,836 | $29,189,922 | 0% | |
| 4. | 25,000,000 | $19,256,425 | 0.37% | |
| 5. | 2,157,781 | $8,393,768 | 0% |
News See All
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Q4 2022 Earnings Call Transcript
Operator: Good day. My name is Andrea, and I will be your conference operator today.
5 Best Medical Stocks Under $5
Geron Corporation (NASDAQ:GERN) is a biopharmaceutical company that is involved in the development of drugs for advanced blood cancers.
Karyopharm Therapeutics Inc (KPTI): Are Hedge Funds Right About This Stock?
Hedge funds and large money managers usually invest with a focus on the long-term horizon and, therefore, short-lived dips or bumps on the charts usually don't make them change their opinion towards a...
Is KPTI A Good Stock To Buy According To Hedge Funds?
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data.
Karyopharm Therapeutics Inc (KPTI): Hedge Fund Sentiment Unchanged
How do you pick the next stock to invest in? One way would be to spend days of research browsing through thousands of publicly traded companies.
Were Hedge Funds Right About Souring On Karyopharm Therapeutics Inc (KPTI)?
At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in (see why hell is coming).
Karyopharm Therapeutics Inc (KPTI): Hedge Funds Taking Some Chips Off The Table
In this article you are going to find out whether hedge funds think Karyopharm Therapeutics Inc (NASDAQ:KPTI) is a good investment right now.
Were Hedge Funds Right About Karyopharm Therapeutics Inc (KPTI)?
We hate to say this but, we told you so.
Hedge Funds Dropped The Ball On Karyopharm Therapeutics Inc (KPTI)
We are still in an overall bull market and many stocks that smart money investors were piling into surged through the end of November.
Billionaire Hedge Funds
